Immix Biopharma, Inc.
IMMX
$2.12
$0.020.95%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 26.31% | 37.48% | 53.69% | 50.75% | 87.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.78% | 13.31% | 40.48% | 58.40% | 74.53% |
| Operating Income | -17.78% | -13.31% | -40.48% | -58.40% | -74.53% |
| Income Before Tax | -20.23% | -13.42% | -39.10% | -54.77% | -68.25% |
| Income Tax Expenses | 19.41% | 40.00% | 55.30% | 62.29% | 83.78% |
| Earnings from Continuing Operations | -20.22% | -13.46% | -39.13% | -54.79% | -68.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -100.00% | -94.22% | -49.85% | 45.66% | 429.95% |
| Net Income | -21.58% | -14.78% | -40.11% | -54.85% | -67.00% |
| EBIT | -17.78% | -13.31% | -40.48% | -58.40% | -74.53% |
| EBITDA | -17.24% | -13.00% | -40.32% | -58.33% | -74.47% |
| EPS Basic | 7.31% | 23.21% | 11.08% | 7.18% | -5.20% |
| Normalized Basic EPS | 6.64% | 22.71% | 10.79% | 7.26% | -4.64% |
| EPS Diluted | 7.31% | 23.21% | 11.08% | 7.18% | -5.20% |
| Normalized Diluted EPS | 6.64% | 22.71% | 10.79% | 7.26% | -4.64% |
| Average Basic Shares Outstanding | 28.18% | 49.01% | 60.49% | 68.38% | 63.08% |
| Average Diluted Shares Outstanding | 28.18% | 49.01% | 60.49% | 68.38% | 63.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |